Skip to main content
SpringerLink
Log in

Therapeutic drug monitoring (TDM) and/or pharmacogenetic tests may be useful in devising individualised drug therapy regimens

  • Practical Issues and Updates
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II

References

  1. Jacquenoud Sirot E, van der Velden JW, Rentsch K, et al. Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance. Drug Saf 2006; 29(9): 735–68

    Article  Google Scholar 

  2. Ozdemir V, Shear NH, Kalow W. What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects? Drug Saf 2001; 24(2): 75–85

    Article  PubMed  CAS  Google Scholar 

  3. Starling RC, Hare JM, Hauptman P, et al. Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. Am J Transplant 2004; 4(12): 2126–31

    Article  PubMed  CAS  Google Scholar 

  4. Eadie MJ. The role of therapeutic drug monitoring in improving the cost effectiveness of anticonvulsant therapy. Clin Pharmacokinet 1995; 29(1): 29–35

    Article  PubMed  CAS  Google Scholar 

  5. Lennard L. Therapeutic drug monitoring of cytotoxic drugs. Br J Clin Pharmacol 2001; 52Suppl. 1: 75S–87S

    Article  PubMed  CAS  Google Scholar 

  6. Lin JH, Yamazaki M. Clinical relevance of P-glycoprotein in drug therapy. Drug Metab Rev 2003; 35(4): 417–54

    Article  PubMed  CAS  Google Scholar 

  7. Sutrop M. Pharmacogenetics: ethical issues. Bioethics 2004; 18(4): iii–viii

    Article  PubMed  Google Scholar 

  8. Xie HG, Kim RB, Wood AJ, et al. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001;41: 815–50

    Article  PubMed  CAS  Google Scholar 

  9. Miners JO, McKinnon RA, Mackenzie PI. Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. Toxicology 2002; 181-2: 453–6

    Article  Google Scholar 

  10. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126(8): 608–14

    PubMed  CAS  Google Scholar 

  11. Liston HL, Markowitz JS, DeVane CL. Drug glucuronidation in clinical psychopharmacology. J Clin Psychopharmacol 2001; 21(5): 500–15

    Article  PubMed  CAS  Google Scholar 

  12. Sakaeda T, Nakamura T, Okumura K. MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull 2002; 25(11): 1391–400

    Article  PubMed  CAS  Google Scholar 

  13. DuBuske LM. The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions. Drug Saf 2005; 28(9): 789–801

    Article  PubMed  CAS  Google Scholar 

  14. Frueh FW, Gurwitz D. From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community. Pharmacogenomics 2004; 5(5): 571–9

    Article  PubMed  Google Scholar 

  15. Phillips KA, Veenstra DL, Oren E, et al. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 2001; 286(18): 2270–9

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Therapeutic drug monitoring (TDM) and/or pharmacogenetic tests may be useful in devising individualised drug therapy regimens. Drugs Ther. Perspect 23, 22–26 (2007). https://doi.org/10.2165/00042310-200723060-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200723060-00007

Search

Navigation